Zivo Bioscience, Inc.
Zivo Bioscience, Inc. is a U.S.-based research and development company focused on proprietary algal and bacterial strains for applications in human health, animal health, and agtech. Its business centers on developing bioactive compounds, algal biomass, and related intellectual property for therapeutic, nutritional, and functional ingredient uses.
Fiscal year 2024 · change from previous year
Development 2019–2024
Business
Share of revenueBioactive materials and product candidates derived from proprietary algae for human and animal health applications.
Cultivated algal biomass sold or developed for food, nutritional, and functional ingredient uses.
License-related economics and participation arrangements tied to ZIVO-derived bioactive ingredients.
Customers
Zivo sells into two broad end markets: animal health and agtech/nutrition. On the biotech side, the company targets partners and eventual end users in poultry, dairy, companion animal, and human health applications; on the agtech side, it sells algal biomass and ingredient products into food, supplement, and skin-care channels.
Buy or license ZIVO-derived solutions for poultry coccidiosis, bovine mastitis, avian influenza, and companion animal health.
Purchase algal biomass for use in green powders, supplements, and fortified food applications.
Partner on late-stage development, regulatory work, and commercialization of bioactive compounds.
Evaluate algal biomass as a functional ingredient for topical and ingestible skin health products.
Strategy
Zivo’s strategy is to advance proprietary algae-derived compounds through regulatory, clinical, and commercial milestones while seeking partners for late-stage development and market access. In parallel, it is scaling algal biomass production and building ingredient sales around Zivolife and related nutrition applications.
Ingredient sales can generate nearer-term revenue while the biotech pipeline matures.
Animal health indications offer a clearer path to value creation and partnering.
GRAS, NDI, and related approvals support broader ingredient and product commercialization.
Development and scale-up require external capital and commercialization partners.
Geography
Zivo is headquartered in the United States, while its algal biomass production is currently located in Peru. The company’s commercialization efforts are aimed at key global markets, with an initial focus on North American food and nutritional powder channels for Zivolife.
Risks
Zivo is exposed to development-stage biotech risk, including uncertain clinical, regulatory, and commercialization outcomes across multiple indications. It also faces funding risk because its business requires ongoing capital to support R&D, production scale-up, and partner-driven commercialization.
The company depends on external capital to fund operations and development.
Product candidates require successful studies and approvals before commercialization.
The company relies on strategic partners for late-stage development and market access.
Commercial algae cultivation must be scaled reliably from pilot to full production.
Ingredient and animal health buyers may prefer established alternatives.
Accounting
Judgemental itemsSales of algal biomass and related contracts may be recognized at different points depending on delivery and performance obligations.
Impact: Affects quarterly revenue timing and comparability
Participation agreements give investors a share of license fees, which can complicate gross vs net presentation and future cash flows.
Impact: Affects revenue presentation and obligations
Non-cash equity awards can be a significant component of R&D and G&A expense in a small development company.
Impact: Affects operating expense and loss measures
Management’s cash runway estimates and funding assumptions are central to financial statement disclosure.
Impact: Affects risk disclosures and valuation judgments
Similar listed companies
Publicly listed companies with a comparable business focus.
Zeo ScientifiX, Inc.
ZEOX · Biological Products, (No Diagnostic Substances)
ZyVersa Therapeutics, Inc.
ZVSA · Pharmaceutical Preparations
Zymeworks Inc.
ZYME · Pharmaceutical Preparations
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
VivoSim Labs, INC.
VIVS · Biological Products, (No Diagnostic Substances)
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026